Journal of Family Planning and Reproductive Health Care 2004: 30(1)

Evidence-based reproductive medicine
Madam I look forward to the arrival of the Journal. It is always a good read, full of relevant and practical information -much more 'user-friendly' than most journals I receive these days. July's edition seemed particularly interesting with a number of interesting articles.
However, my interest was quickly replaced by irritation. There is a lot to be said for evidencebased medicine (EBM) and it is always helpful to have a review of the current evidence available in order to provide women with accurate information when discussing contraception. However, it is not sufficient just to provide the 'evidence'. EBM must consider that clinicians need practical guidance with decision making.
The Clinical Effectiveness Unit (CEU) product review of the desogestrel-only pill is just one example of EBM being unhelpful to our clinical practice. It states: 'an evidence-based recommendation cannot be made that the desogestrel-only pill is different from other POPs in terms of efficacy, nor that it is similar to combined oral contraception (COC) in this respect.' 1 The recommendation is based on insufficient evidence to support lower failure rates with the desogestrel pill. This is despite another study showing that the desogestrel-only pill was sufficient to inhibit ovulation in 97% of cycles and that this is its primary mode of action.
The suggestion that the data provided by the manufacturers may not be credible raises an additional concern. In the same edition an excellent article on evidence-based reproductive health by Robbie Foy quotes a Chinese proverb: 'Be careful what you wish for: it may come true'. 2 The author adds that pharmaceutical industryfunded trials tend to report more favourable findings than those funded by other means, noting that one of the trial authors for the desogestrelonly pill studies is affiliated to the company that manufactures the pill. If this is an issue, then we must equally be assured that none of those undertaking the desogestrel-only pill review have any relevant associations with the manufacturers of other progestogen-only pills (POPs), who are unlikely to welcome this new competitor.
I am not denying the need for more unbiased clinical trial evidence; I am just despairing at our sudden inability to put the information to practical rather than theoretical use. Are we really supposed to tell women that a POP that inhibits ovulation in 97% of cycles is no more effective than currently available POPs?
One 
CEU New Product Review of the desogestrel-only pill
Madam
The Clinical Effectiveness Unit (CEU)'s product review of the desogestrel-only pill 1 and the recent article 'Is Cerazette the minipill of choice?' in the Drug and Therapeutics Bulletin (DTB) 2 are both good reviews of all the relevant studies. But in my opinion they are marred by their surprisingly negative conclusions. What do we do when the evidence from clinical trials and epidemiology is not as complete as we would all like, but we have clients sitting in front of us wanting our help in choosing from the available options? It is then not sufficient just to provide the 'evidence' from an ivory tower. A decision has to be made, at time present. Pending more data, evidence-based medicine (EBM) must be subjected to informed clinical judgement, based on all the available evidence (including the reported pharmacology of the product) and -dare I say it? -clinical common sense.
The statement of the DTB 1 is not inaccurate when it says (in nearly the same words as the CEU 2 ) 'There is insufficient evidence on whether it [Cerazette] is a more effective contraceptive than other POPs in terms of efficacy'. The evidence being alluded to is apparently the single collaborative bleeding pattern and efficacy trial (discussed below). Yet another study showed that the desogestrel-only pill inhibits ovulation in 97% of cycles [compared with only 61-64% of cycles with the levonorgestrel progestogen-only pill (POP)], which (in the CEU review's own words) 'is its primary mode of action'. Since when was such data from a double-blind controlled trial in basic clinical pharmacology not 'evidence'?
The main collaborative European multicentre study was indubitably underpowered, as regards efficacy, in the levonorgestrel POP comparator arm. However, among more than 600 women in the other (desogestrel) arm, who were not breastfeeding and with known gross noncompliance excluded, the Pearl failure rate was only 0.17 (CI 0.004-0.928) per 100 womanyears. Such a low rate (with an upper bound of the CI being less than 1), in any clinical study of a POP over the past 40 years, is historically unprecedented. So it would have been equally valid for the two reviews to have concluded: 'There is insufficient evidence on whether it [Cerazette] is not a more effective contraceptive than other POPs in terms of efficacy'. Indeed, taken with the two studies showing inhibition of ovulation and -something overlooked by both reviews -the fact that Cerazette does not have that inbuilt contraceptive weakness of the combined pill (i.e. the pill-free interval 3 ), I would judge the chances of this product not being ultimately found significantly more effective than other POPs to approach, very closely, to zero. Therefore I consider this product a useful new addition to the range of contraceptives, particularly for a young, non-breastfeeding woman wanting a pill method but recommended, or wishing, to avoid the combined oral contraceptive (COC). It is highly likely (though again this is not yet fully established) to be more forgiving of late pill-taking than other POPs. But users will, as usual for all POPs, need forewarning about the occurrence of irregular bleeding. And I see no special reason to use it in those situations where the combination with a cheaper old-type POP is already virtually 100%, such as in lactation, or in older women, especially those aged over 45 years. 
Reply
Madam On behalf of the FFPRHC Clinical Effectiveness Unit (CEU), I thank you for the opportunity to respond to the letter from Anne MacGregor concerning two articles in the July 2003 issue of the Journal relating to the desogestrel-only pill. I am sorry that your correspondent found the New Product Review from our Unit irritating, rather than clinically useful. We also welcome the opportunity to respond to the letter from John Guillebaud on the same theme.
In my view, our New Product Review 1 provides an utterly objective summary of currently available evidence concerning the desogestrel pill. I stand by our statements that 'on theoretical grounds, we would expect the desogestrel pill to be more effective than existing progestogen-only pills ... but we do not have trial evidence to support this'. The evidence-based reproductive health paper by Foy et al. 2 is commended by your first correspondent but reaches the same conclusion as our New Product Review: 'You cannot tell if the DSG pill is superior or inferior to other POPs'.
Dr MacGregor mentions 'the suggestion that the data provided by the manufacturers may not be credible'. Nowhere in our New Product Review is any comment or suggestion made relating to claims or data provided by the manufacturers. She goes on to seek assurance 'that none of those undertaking the desogestrel-only pill review have any relevant associations with manufacturers of other progestogen-only pills'.
The New Product Review from the CEU does not include an explicit statement of interests. However, CEU staff members are bound by a formal code of practice on 'Relationships with the Pharmaceutical Industry', which was drawn up in consultation with the FFPRHC Clinical Effectiveness Committee soon after the Unit was established. This eight-point code of practice includes the following statements: 'In all aspects of the work of the CEU, staff will be required to appraise the relative benefits of individual contraceptive products and groups of products. Such appraisals will always be conducted in an impartial manner, and be based on available research evidence.' and 'CEU staff should not accept any honoraria or consultancy payments from pharmaceutical companies -either for their personal accounts or for CEU funds'.
Dr MacGregor also comments on the FFPRHC Guidance on Contraceptive Choices for Women with Inflammatory Bowel Disease, 3 developed by our Unit and included in the same issue of the Journal. She feels that we have misrepresented 'Category 3' (risks outweigh benefits) as described in the WHO publication Medical Eligibility Criteria for Contraceptive Use, 4 giving the impression that 'Category 3' equates to absolute contraindication. This was certainly not our intention, and I fully agree with Dr MacGregor's interpretation that 'Category 3' indicates that a method should not be advised as a woman's first choice, but may be used after appropriate counselling. I can only apologise if, in the interests of brevity, this distinction was unclear in this particular FFPRHC Guidance.
